Rapid Diagnostic Testing with BCID2 Panel Improves Time to Optimal Therapy

Many patients with bloodstream infections achieved optimal therapy within 48 hours using the Biofire Blood Culture ...

JUNE 3, 2025

Negative Results on BioFire Pneumonia Panel Allow Antibiotic Discontinuation

A rapid multiplexed molecular panel facilitated safe discontinuation of antibiotic therapy in patients with ...

OCTOBER 25, 2024

FDA Clears bioMérieux Biofire Spotfire R/ST Panel and AST System Vitek Reveal

The FDA cleared two rapid diagnostic panels by bioMérieux—the Biofire Spotfire Respiratory/Sore Throat ...

JULY 1, 2024

Rapid Diagnostic Panel Cuts Time to Effective Therapy for Resistant BSIs

Implementing a rapid diagnostic panel reduced time to effective therapy for resistant bloodstream infections.

MAY 14, 2024

BioFire Sparks Fireworks With Data-Driven Software Solution

The in vitro diagnostics company bioMérieux launched BioFire Fireworks, an innovative and integrated ...

APRIL 6, 2023

National Guidance, Local Implementation: Considerations for Local Blood Culture Identification Guideline Development Using the BIOFIRE^® Blood Culture Identification 2 (BCID2) Panel

The article outlines considerations for the implementation of locally developed testing and treatment guidelines ...

MARCH 31, 2023

FDA Clears New bioMérieux Respiratory Diagnostic System and Panel

The FDA issued a 510(k) clearance and Clinical Laboratory Improvement Amendments (CLIA) waiver for the ...

FEBRUARY 9, 2023